2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
CNS
4
Sarcoma
1
Gynecologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
581
Carboplatin
527
Cisplatin
355
Bevacizumab
256
pembrolizumab
226
Gemcitabine
157
liposomal doxorubicin
132
Topotecan
131
olaparib
129
Cyclophosphamide
126
Radiotherapy
118
Taxes
114
Docetaxel
95
Brachytherapy
94
Drug Therapy
90
niraparib
88
Doxorubicin
86
Surveys and Questionnaires
85
Magnetic Resonance Spectroscopy
80
Blood Specimen Collection
73
Nivolumab
71
Specimen Handling
70
Hyperthermic Intraperitoneal Chemotherapy
64
Biopsy
63
fludarabine
56
Filgrastim
53
Letrozole
50
Oxaliplatin
49
durvalumab
47
Immunoglobulin G
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mebendazole
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn